



Expeditious Formal Synthesis of (±)-Epibatidine Using Diastereoselective Bromohydroxylation of Aminocyclohexene Derivatives

Isabelle Cabanal-Duvillard^a, Jean-François Berrien^b, Jacques Royer^{a*}
and Henri-Philippe Husson^a


(a) Institut de Chimie des Substances Naturelles, CNRS, 91198 Gif-sur-Yvette Cedex, France

(b) Faculté de pharmacie, UMR, CNRS, Biocis 1843, 92296 Châtenay-Malabry Cedex, France

Received 8 April 1998; accepted 15 May 1998

Abstract : Bromination and bromohydroxylation of oxazolidinones derived from cyclohexadiene have been studied in order to synthesize (±)-epibatidine **18**. Bromohydroxylation of compound **2** led to a polyfunctionalized halohydrin **11a** which could be further cyclized to azabicyclo[2.2.1]heptan-2-one **16** already described as a precursor of epibatidine **18**. © 1998 Elsevier Science Ltd. All rights reserved.


The increasing interest in the antinociceptive properties of epibatidine **18**, a frog skin alkaloid, has stimulated several racemic and asymmetric syntheses.¹ We have concentrated our efforts on the synthesis of a key intermediate suitable for the construction of the azabicyclo ring system of epibatidine. In designing a new approach we kept in mind the interest of a possible extension to the optically active series. Here we report an alternative synthesis of *N*-protected-7-aza-bicyclo[2.2.1]heptane-2-one **16**,² a key intermediate for the synthesis of epibatidine, *via* intramolecular cyclization of 1-amino-2,4-dihydro cyclohexane **11a** (Scheme 1). We first studied the reactivity of the double bond of the readily available oxazolidinone **1**³ towards bromination and bromohydroxylation in order to obtain tetrafunctionalized cyclohexanes **5**, **6**, **11a** and **12a** which would hopefully lead to the target molecule.



Scheme 1

Oxazolidinone **1** was easily synthesized from cyclohexadiene following the literature⁴ in 4 steps and 30% overall yield and was converted into tosyl derivative **2** (97% yield) and benzyl derivative **3** (65% yield). Compounds **1**, **2** and **3** were then treated with bromine (Scheme 2).⁵ The choice of a removable bromine atom seemed appropriate for subsequent formation of the bicyclic system.


* fax : 33-(0)-169077247 e.mail : royer@icsn.cnrs-gif.fr



Reagents : (i) NaH, TsCl, 1h, 97% ; (ii) NaH, THF, BnBr, 80°C, 12h, 65% ; (iii) Br₂, CH₂Cl₂, rt

Scheme 2

This reaction proved to be highly diastereoselective for *N*-tosyl derivative **2** since only one addition product **5a** was isolated in 96% yield (¹H NMR : J_{2,3} = 3.5 Hz ; J_{3,4} = 10.0 Hz).⁷ We can assume that electrophilic attack occurred *syn* to the oxazolidinone group⁸ followed by a nucleophilic attack at carbon C-4 for steric hindrance reasons. Compound **5a** was hydrolyzed into alcohol **7** having the required *trans* relationship for cyclization (Scheme 3). Despite numerous attempts, treatment of **7** with a variety of basic conditions⁵ did not lead to bicyclic compound **8** ; only the elimination product *o*-aminophenol **9** was observed. Protection of the hydroxyl function of **7** by a thexyldimethylsilyl group⁹ did not circumvent this difficulty.




Reagents : i) LiOH, MeOH, 95% ii) NaH, THF, rt or *t*-BuOK, THF, -78°C or KOH, MeOH, rt to 80°C

Scheme 3

These results prompted us to the study of bromohydroxylation of **1**, **2** and **3** (Scheme 4). Some halohydroxylations have been reported in the literature as a highly regio- and diastereoselective reaction depending on the substituents.^{10,11}

Two different conditions were investigated : i) NBS (2 equiv.) in DMSO/H₂O (1/1)^{12,13} and ii) Br₂ (2 equiv.) in DME/H₂O (2/1). Under either conditions, and for each compound, a good regioselectivity was observed for the addition reaction, *via* a *trans* addition with hydroxyl ion adding at carbon C-4. However, the diastereoselectivity of the reaction depended on the R substituent and the experimental conditions. Using NBS as bromination agent, it appeared that the bromonium ion was formed predominantly *anti* to the oxazolidinone function, probably under steric control.⁸

Diastereomers **10b** ($^1\text{H NMR}$: $J_{2,3} = 8.1\text{Hz}$ and $J_{3,4} = 10.1\text{Hz}$) and **12b** were isolated as the major products. The reaction of Br_2 in DME/ H_2O with tosyl oxazolidinone **2** proceeds by the same mechanism as for the dibromination, *i.e.* a *syn* electrophilic attack of bromonium ion and hydroxyl addition at carbon C-4 to give compound **11a** ($^1\text{H NMR}$: $J_{2,3} = 3.7\text{Hz}$ and $J_{3,4} = 10.0\text{Hz}$)¹⁴ as the major product. Surprisingly, reverse diastereoselectivity was observed in these conditions for oxazolidinone **1**, which gave compound **10b** as the major product.




Reagents : (i) NBS (2 equiv.) DMSO/ H_2O (1/1), rt ; (ii) Br_2 (2 equiv.) DME/ H_2O . rt

Scheme 4

Better results for cyclization were expected with bromhydrin **11a**, obtained in 60% yield, since bromine in this case could be selectively removed before cyclization.

The diol **14** was isolated in 80% yield after radical reductive removal of bromine¹⁵ from **11a**, followed by hydrolysis of the oxazolidinone function (Scheme 5). Cyclization under Mitsunobu's conditions¹⁶ gave the bicyclic compound **15** in 90% yield. Oxidation of the hydroxyl function of compound **15** following the Swern procedure¹⁷ afforded the ketone **16**² in 88% yield. Intermediate **16**, whose spectral data are in full agreement with those reported,¹⁸ has been previously converted to epibatidine.



Reagents : (i) AIBN, Bu_3SnH , 70°C ; (ii) LiOH , MeOH , rt ; (iii) PPh_3 , DEAD, THF, rt ; (iv) $(\text{COCl})_2$, DMSO, Et_3N

Scheme 5

In conclusion we have prepared the azabicyclo[2.2.1]heptane-2-one **16** in 5 steps and 37% overall yield starting from oxazolidinone **1**.

These results compare favorably with previous approaches and it is also expected that this strategy could be adapted for optically active syntheses.

References and notes

- (a) Spande, T. F.; Garraffo, H. M.; Edwards, M. W.; Yeh, H. J. C.; Pannell, L.; Daly, J. W. *J. Am. Chem. Soc.* **1992**, *114*, 3475-3478. (b) Daly, J. W. *J. Nat. Prod.* **1998**, *61*, 162-172.; For reviews : see : (c) Dehmlow, E. V. *J. Prakt. Chem.* **1995**, *337*, 167-174. (d) Szantay, C.; Kardos-Balogh, Z.; Szantay Jr., C. *The Alkaloids* (G. A. Cordell Ed.) **1995**, *46*, 95-125. For more recent syntheses : (e) Trost, B. M.; Cook, G. R. *J. Org. Chem.* **1996**, *37*, 7485-7488. (f) Xu, R.; Chu, G.; Bai, D. *J. Org. Chem.* **1996**, *61*, 4600-4606. (g) Zhang, C.; Gyermek, L.; Trudell, M. L. *Tetrahedron Lett.* **1997**, *38*, 5619. (h) Kosugi, H.; Abe, M.; Uda, H.; Kato, M. *J. Chem. Soc. Chem. Comm.* **1997**, 1857. (i) Trudell, M. L. *Tetrahedron Lett.* **1997**, *38*, 7993. (j) Sirisoma, N. S.; Johnson, C. R. *Tetrahedron Lett.* **1998**, *39*, 2059-2062.
- (a) Hernandez, A.; Marcos, M.; Rapoport, H. *J. Org. Chem.* **1995**, *60*, 2683-2691. (b) Okabe, K.; Natsume, M. *Chem. Pharm. Bull.* **1994**, *42*, 1432-1436.
- (a) Knapp, S.; Kukkola, P. J.; Sharma, S.; Murali Dhar, T. G.; Naughton, A. B. *J. Org. Chem.* **1990**, *55*, 5700-5710. (b) Knapp, S.; Kukkola, P. J.; Sharma, S.; Pietranico, S. *Tetrahedron Lett.* **1987**, *28*, 5399-5402.
- In our hands, bromohydroxylation of cyclohexadiene was accomplished in 47% yield following the Dalton's procedure : Dalton, D. R.; Dutta, V. P.; Jones, D. C. *J. Am. Chem. Soc.* **1968**, *90*, 5498-5501.
- Dibromination of the double bond of a functionalized cyclohexene has been reported by Corey's group and proved to be totally diastereoselective : Corey, E. J.; Loh, T. -P.; AchyuthaRao, S.; Daley, D. C.; Sarshar, S. *J. Org. Chem.* **1993**, *58*, 5600-5602.
- Compounds **4a** et **4b** showing some instability, and could not be isolated separately by chromatography on silica gel. The product ratio was determined as 65/35 by NMR analysis but the major product could not be identified.
- Compound **5a** : $^1\text{H NMR } \delta(\text{ppm})$: 7.9 (2H, d, $J = 8.0$ Hz) ; 7.3 (2H, d, $J = 8.0$ Hz) ; 4.8 (1H, dd, $J = 3.3$ Hz, $J = 6.0$ Hz) ; 4.6 (1H, td, $J_t = 6.0$, $J_d = 8.0$) ; 4.25 (1H, dd, $J = 3.5$, $J = 10.0$) ; 3.45 (1H, dd, $J = 4.4$, $J = 10.0$) ; 2.55 (3H, s) ; 2.2-1.4 (4H, m). IR (cm^{-1}) : 1785 (ν CO) ; 1363 ; 1162 (ν SO₂). MS : 456/454/452 (MH^+).
- (a) Bellucci, G.; Berti, G.; Ingrosso, G.; Mastroilli, E. *Tetrahedron Lett.* **1973**, 3911-3914. (b) Goering, B. K.; Ganem, B. *Tetrahedron Lett.* **1994**, *35*, 6997-6700.
- Wetter, H.; Oertle, K. *Tetrahedron Lett.* **1985**, *26*, 5515.
- (a) Mévellec, L.; Evers, M.; Huet, F. *Tetrahedron* **1996**, *52*, 15103-15116. (b) Mévellec, L.; Huet, F. *Tetrahedron*, **1994**, *50*, 13145-13154.
- Mévellec, L.; Evers, M.; Huet, F. *Tetrahedron* **1997**, *53*, 5797-5812.
- Sisti, A. J. *J. Org. Chem.* **1970**, *35*, 2670-2673.
- Guss, C. O. ; Rosenthal, R. *J. Am. Chem. Soc.* **1955**, *77*, 2549.
- Compound **11a** : $^1\text{H NMR } \delta(\text{ppm})$: 7.95 (2H, d, $J = 8.3$) ; 7.45 (2H, d, $J = 8.3$) ; 5.6 (1H, d, $J = 5.5$) ; 5.15 (1H, dd, $J = 3.7$, $J = 5.8$) ; 4.75 (1H, td, $J_t = 5.9$, $J_d = 6.0$) ; 4.35 (1H, dd, $J = 3.7$, $J = 10.0$) ; 3.7 (1H, ddt, $J_d = 5.3$, $J_d = 5.0$, $J_t = 10.1$) ; 2.5 (3H, s) ; 2.4-2.3 (1H, m) ; 1.9 (1H, m) ; 1.60-1.45 (1H, m) ; 1.45-1.30 (1H, m). IR (cm^{-1}) : 3300 (ν OH) ; 1785 (ν CO) ; 1370 ; 1173 (ν SO₂). MS : 395/390 (MH^+) ; 238/236.
- Bonini, C. ; Righi, G. ; Sotgiu, G. *J. Org. Chem.* **1991**, *56*, 6206-6209.
- (a) Mitsunobu, O. *Synthesis* **1981**, 1-28. (b) Grandel, R.; Kazmaier, U. *Tetrahedron Lett.* **1997**, *38*, 8009-8012.
- Fletcher, S. R.; Baker, R.; Chambers, M. S.; Herbert, R. H.; Hobbs, S. C.; Thomas, S. R.; Verrier, H. M.; Watt, A. P.; Ball, R. G. *J. Org. Chem.* **1994**, *59*, 1771-1778.
- Compound **16** : $^1\text{H NMR } \delta(\text{ppm})$: 7.8 (2H, d, $J = 8.0$) ; 7.3 (2H, d, $J = 8.0$) ; 4.25 (1H, t, $J = 4.3$) ; 4.0 (1H, d, $J = 4.1$) ; 3.85 (1H, ddd, $J = 2.5$, $J = 7.5$, $J = 10.1$) ; 2.6 (1H, d, $J = 10.4$) ; 2.0-1.4 (6H, m). IR (cm^{-1}) : 3400 (ν OH) ; 1317 ; 1151 (ν SO₂). MS : 268 (MH^+) ; 157; 155.